2020
577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy
Perreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy. Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.Peer-Reviewed Original ResearchSurveillance blood culturesBlood culturesGVHD patientsSteroid therapyDay mortalitySurveillance culturesPositive culturesHematopoietic stem cell transplant patientsGraft Versus Host DiseaseStem cell transplant patientsBlood culture positivity rateYale-New Haven HospitalSymptoms of GVHDVersus Host DiseaseCell transplant patientsNumber of patientsLack of symptomsCulture positivity rateDiagnosis of infectionNew Haven HospitalRisk of infectionCoagulase-negative staphylococciActive GVHDHost diseaseMedian dose
2019
2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT). Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.Peer-Reviewed Original ResearchAutologous hematopoietic stem cell transplantationHematopoietic stem cell transplantationPost-hematopoietic stem cell transplantationAutologous HSCT patientsAerosolized pentamidinePJP prophylaxisHSCT patientsPJP infectionYear post-hematopoietic stem cell transplantationYale-New Haven HospitalRisk of cytopeniaHigh-dose corticosteroidsStem cell transplantationNew Haven HospitalYears of ageCost of drugsAP prophylaxisDose corticosteroidsJiroveci infectionMonth regimenPrimary endpointRelapsed diseaseSecondary endpointsImmunomodulatory drugsRetrospective study
2018
2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?
Ahmad H, Perreault S, McManus D, Foss F, Isufi I, Seropian S, Topal J. 2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum Infectious Diseases 2018, 5: s746-s746. PMCID: PMC6255683, DOI: 10.1093/ofid/ofy210.2140.Peer-Reviewed Original ResearchVaccination seriesHSCT patientsDisease relapseCommon reasonHematopoietic stem cell transplant patientsCompliance ratePost-vaccination antibody responseStem cell transplant patientsYale-New Haven HospitalAdult HSCT patientsAutologous HSCT patientsIncomplete vaccination seriesPost-transplant vaccinationPost-vaccination titersCell transplant patientsVaccine-preventable infectionsLoss of immunogenicityNew Haven HospitalYears of ageImmunization adherenceMaintenance chemotherapyRoutine revaccinationHost diseaseImmunosuppressive therapyPrimary endpoint